Beating diabetes with B-cell-targeting drugs
This article was originally published in Scrip
Executive Summary
Biogen Idec/Genentech's approved anticancer drug Rituxan (rituximab) met primary and secondary efficacy endpoints in a Phase II trial in type 1 diabetes patients, shows a National Institutes of Health-funded trial. The study, published in the NEJM, provides general support for the development of antidiabetic agents that target B-cells.